Mark Carbonneau

Mark Carbonneau

Company: Synlogictx

Job title: Sr. Director, Head of Translational Science


Development of a Synthetic Biotic for the Treatment of Phenylketonuria 3:30 pm

Phenylketonuria is a rare inherited disorder of Phenylalanine metabolism, with significant risk of neurocognitive impairment and high unmet need Our team at Synlogic has developed SYNB168, an engineered Synthetic Biotic to consume Phe in the GI tract that demonstrated fasting plasma Phe lowering in patients with PKU The SYNB1618 clinical data validate Synlogic’s mathematical modeling…Read more

day: Day One – Track B – 2

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.